Roche trials database

Protocol Number: WV15376

Product Name: Valcyte [valganciclovir]

Date of Report: 01.03.2004

Phase: III

A Randomized Controlled Comparison of the Safety and Efficacy of Ro107-9070 (Valganciclovir) vs Intravenous Ganciclovir as Induction Therapy for the Treatment of Newly Diagnosed Cytomegalovirus Retinitis

Protocol Number: NV25409

Product Name: Valcyte [valganciclovir]

Date of Report: To be Published

Phase: IV

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

Protocol Number: NP22523

Product Name: Valcyte [valganciclovir]

Date of Report: To be Published

Phase: I

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients less than 4 Months of Age

Protocol Number: WV25651

Product Name: Valcyte [valganciclovir]

Date of Report: To be Published

Phase: IV

An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls

Protocol Number: WV15705

Product Name: Valcyte [valganciclovir]

Date of Report: 01.03.2004

Phase: III

An Open-Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects with AIDS

Protocol Number: WV16726

Product Name: Valcyte [valganciclovir]

Date of Report: 30.11.2007

Phase: II

Safety and pharmacokinetics of valganciclovir syrup formulation in pediatric solid organ transplant recipients.

Protocol Number: ML16420

Product Name: Valcyte [valganciclovir]

Date of Report: 04.03.2005

Phase: II

The pharmacokinetics of ganciclovir following a dose of valganciclovir vs iv ganciclovir in bone marrow transplant or human stem cell transplant (BMT/HSCT) patients with stable graft-versus-host disease (GVHD) who have gut involvement